(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Reviva Pharmaceuticals Holdings's earnings in 2025 is -$28,918,034.On average, 3 Wall Street analysts forecast RVPH's earnings for 2025 to be -$27,889,728, with the lowest RVPH earnings forecast at -$38,326,758, and the highest RVPH earnings forecast at -$20,565,578. On average, 2 Wall Street analysts forecast RVPH's earnings for 2026 to be -$20,331,878, with the lowest RVPH earnings forecast at -$25,239,572, and the highest RVPH earnings forecast at -$15,424,183.
In 2027, RVPH is forecast to generate -$7,478,392 in earnings, with the lowest earnings forecast at -$7,478,392 and the highest earnings forecast at -$7,478,392.